DALLAS, July 8, 2015 /PRNewswire/ --
ReportsnReports.com adds Acromegaly - Pipeline Review, H1 2015 market research report that provides an overview of the Acromegaly's therapeutic pipeline and helps strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete market report on acromegaly pipeline for H1 2015 spread across 91 pages, talking about 14 companies and supported with 32 tables and 14 Figures is now available at http://www.reportsnreports.com/reports/403914-acromegaly-pipeline-review-h1-2015.html .
The Acromegaly - Pipeline Review, H1 2015 market research report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. The research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies and helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. It is useful to develop strategic initiatives by understanding the focus areas of leading companies and in identifying and understanding important and diverse types of therapeutics under development for Acromegaly. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline, devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics, develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope as well as modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline, easily, by utilizing the data and information on acromegaly presented in this pipeline research report.
Companies Involved in acromegaly therapeutics development and mentioned in this pipeline review report include Aegis Therapeutics, LLC, Antisense Therapeutics Limited, Chiasma, Inc., Crinetics Pharmaceuticals, Inc., DexTech Medical AB , Foresee Pharmaceuticals, LLC, GP Pharm, S.A., Ipsen S.A., Isis Pharmaceuticals, Inc, Italfarmaco S.p.A., Novartis AG, Paladin Labs Inc., Peptron, Inc. and Sompharmaceuticals S.A. Drug profiles described in this research include ATL-1103, BIM-23A758, DG-3173, FP-002, G-02113, ISIS-GHRLRx, ITF-2984, L-779976, octreotide, octreotide acetate, octreotide acetate LAR, octreotide acetate long acting, octreotide acetate SR, octreotide SR, pasireotide LAR, pegvisomant, Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders, Somadex, SXN-101742 and SXN-101959. Order a copy of Acromegaly - Pipeline Review, H1 2015 market research report at http://www.reportsnreports.com/Purchase.aspx?name=403914 .
Featured News & Press Releases from 2015 on the acromegaly sector included in this research covers:
Apr 16, 2015: ATL1103 - New European Patent Application Allowance
Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015
Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence
Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules
Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly
Jan 26, 2015: Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product
Figures provided in this acromegaly pipeline report include:
Number of Products under Development for Acromegaly, H1 2015
Number of Products under Development for Acromegaly - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
On a related note, ReportsnReports.com also offers EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023 that forecasts an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%. This research provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending at ?75 years in acromegaly cases, and beginning at 0 years and ending at ?75 years in gigantism cases), type of pituitary adenoma (macroadenoma or microadenoma), and whether any surgical intervention was received in these markets. The acromegaly and gigantism epidemiology report is written and developed by Mastersand PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM. Read more at http://www.reportsnreports.com/reports/319968-epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023.html .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252